Apoptosis in squamous cell carcinoma of the lung: correlation with survival and clinicopathological features

Aims—Apoptosis is recognised as a physiological mechanism for controlling cell numbers and its subversion is thought to contribute to carcinogenesis. The aims of this study were to measure the apoptotic index (AI) in a series of squamous cell carcinomas (SCCs) of the lung using standard histological staining and confirm this by immunohistology using an antibody to an apoptosis specific protein (ASP), and to seek to correlate the AI with clinicopathological parameters. Methods—Sections of 134 SCCs were stained by haematoxylin and eosin (H&E) for counting apoptotic bodies to determine the AI (number of apoptotic bodies/10 000 tumour cells); 26 of these were also stained with anti-ASP antibody and the proportion of ASP positive cells counted. Clinical data were obtained from hospital notes. Results—The mean AI obtained by H&E staining of all 134 SCCs was 30.3 (SD, 24.75). Anti-ASP staining allowed easy identification of apoptotic bodies, and generated a somewhat higher index (mean, 51.4; SD 39); this was not a result of the selection of tumours because the AI by H&E in the subset stained with anti-ASP was 31.1. Regression analysis showed that the correlation between the two values of AI was highly significant (Rs = 0.9760; p < 0.001), indicating that the two methods were both reliable measures of apoptosis but that the anti-ASP staining is the more sensitive method. The tumours were grouped into high AI (> 50) and low AI (< 50) and survival analysis was carried out. The mean survival of the high AI group was 109 weeks and of the low AI group 72 weeks (p = 0.036). Conclusions—Anti-ASP staining is a reliable, easy, and sensitive method for assessing apoptosis in tumour sections and confirms the validity of the AI obtained by H&E staining. AI is a guide to the behaviour of SCCs of the lung.

[1]  J. D. Jong,et al.  Number of apoptotic cells as a prognostic marker in invasive breast cancer , 2000, British Journal of Cancer.

[2]  D. Owen,et al.  A novel protein expressed in mammalian cells undergoing apoptosis. , 1995, Experimental cell research.

[3]  C. Winterford,et al.  Apoptosis. Its significance in cancer and cancer Therapy , 1994, Cancer.

[4]  S. Ben‐Sasson,et al.  Identification of programmed cell death in situ via specific labeling of nuclear DNA fragmentation , 1992, The Journal of cell biology.

[5]  J. Robb,et al.  Apoptosis in human breast and gastrointestinal carcinomas. Detection in histological sections with monoclonal antibody to single-stranded DNA. , 1996, Anticancer Research.

[6]  M. Saegusa,et al.  Correlation of apoptosis with tumour cell differentiation, progression, and HPV infection in cervical carcinoma. , 1996, Journal of clinical pathology.

[7]  K. Ohshima,et al.  Apoptosis and proliferation in gastric carcinoma: the association with histological type , 1996, Histopathology.

[8]  P. Lipponen,et al.  Histological grade, perineural infiltration, tumour-infiltrating lymphocytes and apoptosis as determinants of long-term prognosis in prostatic adenocarcinoma. , 1994, European journal of cancer.

[9]  M. Volm,et al.  Apoptosis in non-small cell lung cancer as related to drug resistance and prognosis , 1996, Apoptosis.

[10]  M. Gilthorpe,et al.  Interphase nucleolar organiser regions and survival in squamous cell carcinoma of the bronchus: a 10 year follow up study of 138 cases. , 1991, Thorax.

[11]  G. Baretton,et al.  Apoptosis and immunohistochemical bcl‐2 expression in colorectal adenomas and carcinomas: Aspects of carcinogenesis and prognostic significance , 1996, Cancer.

[12]  J. Hendry,et al.  Apoptosis, intrinsic radiosensitivity and prediction of radiotherapy response in cervical carcinoma. , 1995, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[13]  G. Baretton,et al.  bcl-2 expression, p53 accumulation, and apoptosis in ovarian carcinomas. , 1996, American journal of clinical pathology.

[14]  Y. Soini,et al.  Apoptosis in operated small cell lung carcinoma is inversely related to tumour necrosis and p53 immunoreactivity , 1997, The Journal of pathology.

[15]  M. Saegusa,et al.  Apoptosis, cell proliferation and expression of Bcl-2 and Bax in gastric carcinomas: immunohistochemical and clinicopathological study. , 1997, British Journal of Cancer.

[16]  J. H. Dierendonck,et al.  A new method to detect apoptosis in paraffin sections: in situ end-labeling of fragmented DNA. , 1993, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.

[17]  M. Samoszuk,et al.  Association between flow cytometric S-phase fraction and apoptotic rate in breast cancer. , 1996, Cytometry.

[18]  B. Lloveras,et al.  Apoptosis loss and bcl-2 expression: key determinants of lymph node metastases in T1 breast cancer. , 1996, Clinical cancer research : an official journal of the American Association for Cancer Research.

[19]  S. Aktaş,et al.  Apoptosis bcl-2 and p53 expression and their relation to tumour stage in non-small cell lung carcinomas (NSCLC). , 1997, Cancer letters.

[20]  P. V. van Diest,et al.  Counting of apoptotic cells: a methodological study in invasive breast cancer , 1996, Clinical molecular pathology.

[21]  G. Reynolds,et al.  Simple method for pretreatment of tissue sections for the detection of apoptosis by in situ end-labelling and in situ nick translation , 1996, Clinical molecular pathology.

[22]  P. Lipponen,et al.  Apoptosis in bladder cancer as related to standard prognostic factors and prognosis , 1994, The Journal of pathology.

[23]  V. Kosma,et al.  Apoptosis in breast cancer as related to histopathological characteristics and prognosis. , 1994, European journal of cancer.